Cytogen

Cytogen EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Cytogen (217330.KQ) as of Oct 15, 2026 is -13.17. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.53 — a change of 75.04% (lower).

EV/FCF

-13.17

YoY

75.04%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Cytogen is 2025 -13.17 . EV/FCF (Enterprise Value to Free Cash Flow) of Cytogen was 2024 -7.53 . It decreases by 75.04% lower compared to the previous year.

The Cytogen EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-21.56 KRW
Jan 1, 2019
-24.40 KRW
Jan 1, 2020
-20.56 KRW
Jan 1, 2021
-12.91 KRW
Jan 1, 2022
-12.89 KRW
Jan 1, 2023
-6.11 KRW
Jan 1, 2024
-7.53 KRW
Jan 1, 2025
-13.17 KRW
The Cytogen EV/FCF history
YEAREV/FCFYoY
-13.17+75.04%
-7.53+23.11%
-6.11-52.58%
-12.89-0.12%
-12.91-37.22%
-20.56-15.73%
-24.40+13.17%
-21.56-48.16%
-41.59+5.07%
-39.58-10.80%
-44.37+90,169.03%
-0.05—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cytogen Stock analysis

What does Cytogen do? Cytogen Inc, listed on the Korean stock market with ticker 217330.KQ and ISIN KR727330000, is a biotechnology company based in Seoul, South Korea. The company, which went public on November 22, 2018, employs 43 full-time staff. Cytogen Inc focuses on the research and development of cancer treatment solutions, particularly in the field of liquid biopsy applications. Its services include biomarker discovery and verification, such as circulating tumor cell (CTC)-based biomarker analysis, gene mutation and transcript expression studies, and drug testing. The company also provides liquid biopsy-based precision medical services, including companion diagnostics development, therapeutic drug re-selection, treatment effectiveness monitoring, and recurrence prediction. Cytogen Inc develops and sells platforms and kits for liquid biopsy, distributing its products domestically in South Korea and internationally. The company's website is http://www.cytogenlab.com. As a biotechnology firm operating within the healthcare sector, Cytogen Inc is engaged in advancing cancer diagnostics and treatment through innovative liquid biopsy technologies. Cytogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cytogen stock

EV/FCF (Enterprise Value to Free Cash Flow) of Cytogen is -13.17 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Cytogen changed from -7.53 to -13.17, representing a 75.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Cytogen since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Cytogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cytogen

All Key Metrics — Cytogen